08 aug 25   futura medical plc - board changes, business update & notice of results futura medical plc | fum | 11.5 0 0.0% | mkt cap: 35.0m    rns number : 5061u futura medical plc 08 august 2025   8 august 2025   futura medical plc ("futura" or the "group")   board changes, business update and notice of interim results   futura medical plc (aim: fum), is pleased to announce that, further to the board changes announced on 8 july 2025, alex duggan has been appointed to the board of directors as interim chief executive officer. this follows the completion of all required due diligence and regulatory checks. alex brings over 25 years of leadership experience in the consumer healthcare and prescription (rx) sectors. he has a proven track record of driving business transformation through m&a, operations and organic growth across global markets.   the group also announces that angela hildreth has notified the board of her intention to step down as finance director and chief operating officer. angela will remain in her role and as a director of the company during her six-month notice period, continuing to support the group and overseeing an orderly handover of responsibilities once a successor has been appointed. the board would like to thank angela for her significant contribution and commitment to the business throughout her tenure.   business update   as a new product in a new category, eroxon sales performance remains unpredictable and sales trends (including the impact of previous channel fill) remain challenging to identify and predict. the momentum of sales of eroxon continues to be slower than originally anticipated, with varying degrees of traction across different territories.   reflecting on this slower momentum, alongside the challenges and learnings from eroxon's initial product launches, the board, led by alex duggan, is conducting a thorough review of the current business and its commercial plans. this includes, but is not limited to, the company's sales and marketing strategies for eroxon as well as the costs associated with the business and other possible strategic options available to the group.   the board anticipates that it will be able to provide an initial update on its review of the business and strategy at the time of its interim results, which are currently expected to be published in late september.    andrew unitt, senior independent director, commented:   "we are pleased to formally welcome alex to the board. his experience and decisive leadership will undoubtably prove instrumental at this phase of the group's development.   we are grateful to angela for her many years of dedicated service to the company, during which she oversaw a period of significant development. we wish her all the best in her next chapter."   alex duggan, ceo of futura, commented:   "i am pleased to join the board and to step into the interim ceo role at this pivotal juncture for the group. i will be working closely with the board and the wider team in my review of the business, its priorities, and its strategic options over the period ahead. our priority is to deliver a clear strategy that will maximise value for shareholders, commercial partners and employees."   in accordance with schedule 2 paragraph (g) of the aim rules for companies, alexander james hanbury duggan (aged 54 years) holds/has held the following directorships/partnerships in the last five years:   current past 5 years cryotag limited maelor laboratories limited appia healthcare limited alliance pharmaceuticals limited amd consulting limited proprietary association of great britain  opus healthcare limited  alliance pharma (ireland) limited  alliance pharmaceuticals sas  alliance pharma france sas  alliance pharmaceuticals gmbh  alliance pharma srl  alliance pharmaceuticals spain sl  advanced bio-technologies, inc  alliance pharma inc  alliance pharmaceuticals (asia) ltd  synthasia international company ltd  alliance pharma (singapore) pte ltd  alliance pharmaceuticals (thailand) co., ltd  alliance pharmaceuticals (philippines) corp  alliance chc (india) pte ltd   alexander duggan was a director of the paradigm organisation ltd, appointed on 26 june 1996. following a court order to wind up the business on 21 october 1997, alexander duggan resigned as a director on 24 october 1997 and the company dissolved on 10 april 2000.   there are no further disclosures to be made pursuant to schedule 2 paragraph (g) of the aim rules for companies.   the information communicated in this announcement contains inside information for the purposes of article 7 of the market abuse regulation (eu) no. 596/2014 as amended by the market abuse (amendment) (eu exit) regulations 2019.   contacts:   futura medical plc       alex duggan interim chief executive officer   investor.relations@futuramedical.com +44 (0)1483 685 670 www.futuramedical.com   panmure liberum nominated adviser and broker   emma earl, will goode, mark rogers (corporate finance) rupert dearden (corporate broking) +44 (0)20 3100 2000        alma strategic communications rebecca sanders-hewett sam modlin emma thompson +44 (0)20 3405 0205 futura@almastrategic.com    notes to editors:   futura medical plc (aim: fum) is the developer of innovative sexual health products, including lead product eroxon® and products wsd4000 and eroxon® intense. our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.   sexual health issues are prevalent in both men and women. ed impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ed and 25% of all new diagnoses being in men under 40. around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.   eroxon®, futura's clinically proven lead product, has been developed for the treatment of erectile dysfunction ("ed"). the highly differentiated product, which is the only topical gel treatment for ed available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ed market. eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.   futura has distribution partners in place in a number of major consumer markets including haleon in the us, the largest market for ed in the world, and cooper consumer health in europe. this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   boaupuaprupapgm return to news summary

Label: Gestiegen